Loading…

Medical Research Finder

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

Adenosine & Cancer Immunotherapy / Immuno-Oncology

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Increasing evidence supports targeting the adenosine pathway in Cancer Immunotherapy / Immuno-Oncology with several clinical programs directed at adenosine A2 receptor (A2AR, A2BR ), CD73 , and CD39 in development.
Augustin et al. 2022 Journal for ImmunoTherapy of Cancer 10: e004089

A perpetuating cycle of tumor cell proliferation, tissue injury, dysregulated angiogenesis, and [hypoxia](brain://n6RbLkJNTlG69kts4nR3Xw/Hypoxia…

A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy
Leone et al. 2015
Review
Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade
Yang et al. 2020c
Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models
Leone et al. 2018 Cancer Immunol Immunother 67(8): 1271-1284
Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy
Augustin et al. 2022 Journal for ImmunoTherapy of Cancer 10: e004089
Review
The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets
Allard et al., 2017
Review

7/1/2026